Nadine Rouphael

Learn More
BACKGROUND Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs. METHODS A multicenter, randomized, blinded phase 1 clinical trial evaluated safety and antibody responses after point-of-use(More)
Background.  We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine. Methods.  Sixty healthy, HIV-1-uninfected adults were enrolled in a randomized, double-blinded, placebo-controlled dose-escalation study.(More)
Antibody responses and cytokines induced by Meningococcal vaccines. (a) ELISPOT captured day 7 IgG antibody-secreting cells (ASCs) in a subset of vaccinees. Plates were coated with goat anti human IgG antibody, MCV4, DT or MPSV4 and detected with anti human IgG biotin and streptavidin HRP. (b) Two representative subjects are shown. On the left, 1X(More)
Human herpesviruses are important causes of potentially severe chronic infections for which T cells are believed to be necessary for control. In order to examine the role of virus-specific CD8 T cells against Varicella Zoster Virus (VZV), we generated a comprehensive panel of potential epitopes predicted in silico and screened for T cell responses in(More)
Background.  Mortality for cryptococcal meningitis remains significant, in spite of available treatment. Resistance to first-line maintenance therapy, particularly fluconazole, has been reported. Methods.  A retrospective chart review was performed on immunocompromised patients with cryptococcal meningitis, who had susceptibility testing performed between(More)
  • 1